{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:18:34Z","timestamp":1784546314045,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2025.08.007","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T01:24:09Z","timestamp":1755825849000},"page":"e430-e441.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic Impact of the Level of Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation on Pediatric Patients With Acute Lymphoblastic Leukemia: A 10-Year Single-Center Study"],"prefix":"10.1016","volume":"26","author":[{"given":"Wei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoquan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenguang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.08.007_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1191912","article-title":"Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia","volume":"14","author":"Hodroj","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.clml.2025.08.007_bib0002","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17474086.2022.2125375","article-title":"Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective","volume":"15","author":"Ma","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"16","key":"10.1016\/j.clml.2025.08.007_bib0003","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMe2403003","article-title":"CAR as booster to launch allogeneic transplantation in refractory leukemia","volume":"390","author":"Blaise","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.clml.2025.08.007_bib0004","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1182\/bloodadvances.2020002945","article-title":"Allogeneic transplantation for ph+ acute lymphoblastic leukemia with post transplantation cyclophosphamide","volume":"4","author":"Webster","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2025.08.007_bib0005","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-21-3959","article-title":"Progress in transplants for acute lymphoblastic leukemia","volume":"28","author":"Gale","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.clml.2025.08.007_bib0006","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.clml.2025.08.007_bib0007","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","article-title":"Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2025.08.007_bib0008","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European Leukemia Net MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.08.007_bib0009","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jtct.2022.01.014","article-title":"Post-transplantation multicolored flow cytometry-minimal residual disease status on day 100 predicts outcomes for patients with refractory acute myeloid leukemia","volume":"28","author":"Klyuchnikov","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.clml.2025.08.007_bib0010","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/ajh.26993","article-title":"Minimal residual disease in Philadelphia-positive acute lymphoblastic leukemia: maximizing the clinical yield of testing","volume":"98","author":"Saliba","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.08.007_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1047554","article-title":"Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Tecchio","year":"2023","journal-title":"Front Oncol"},{"issue":"suppl 5","key":"10.1016\/j.clml.2025.08.007_bib0012","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.08.007_bib0013","doi-asserted-by":"crossref","first-page":"563","DOI":"10.6004\/jnccn.2024.0051","article-title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.clml.2025.08.007_bib0014","first-page":"793","article-title":"Chinese Society of Hematology, Chinese Medical Association; Chinese Pediatric Society, Chinese Medical Association. Chinese expert consensus of allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia (2022) . [J]","volume":"43","year":"2022","journal-title":"Chin J Hematol"},{"key":"10.1016\/j.clml.2025.08.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101035","article-title":"Haploidentical transplants with a G-CSF\/ATG-based protocol: experience from China","volume":"62","author":"Xu","year":"2023","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.clml.2025.08.007_bib0016","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.22.00767","article-title":"Busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for adults acute B lymphoblastic leukemia: an open-label, multicenter, phase III trial","volume":"41","author":"Zhang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.08.007_bib0017","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2023020073","article-title":"Novel developments in the prophylaxis and treatment of acute GVHD","volume":"142","author":"Jamy","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.08.007_bib0018","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41409-024-02370-8","article-title":"Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era","volume":"59","author":"Vadakkel","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.08.007_bib0019","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00277-023-05506-w","article-title":"Allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia","volume":"103","author":"Tian","year":"2024","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.08.007_bib0020","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cyto.b.21855","article-title":"Leukemia-associated immunophenotypes subdivided in \"categories of specificity\" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia","volume":"98","author":"Rossi","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"issue":"23","key":"10.1016\/j.clml.2025.08.007_bib0021","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.4103\/0366-6999.246072","article-title":"Association of persistent minimal residual disease with poor outcomes of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"131","author":"Liu","year":"2018","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"10.1016\/j.clml.2025.08.007_bib0022","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-Host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.08.007_bib0023","first-page":"1","article-title":"Acute graft-versus-host disease: a brief review","volume":"37","author":"Alada\u011f","year":"2020","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.clml.2025.08.007_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1047554","article-title":"Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Tecchio","year":"2023","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.08.007_bib0025","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/ajh.26993","article-title":"Minimal residual disease in Philadelphia-positive acute lymphoblastic leukemia: maximizing the clinical yield of testing","volume":"98","author":"Saliba","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.08.007_bib0026","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/ijms21031054","article-title":"Minimal residual disease detection in acute lymphoblastic leukemia","volume":"21","author":"Kruse","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.clml.2025.08.007_bib0027","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/bjh.17424","article-title":"Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia","volume":"193","author":"Wang","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.08.007_bib0028","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2002.3311a.x","article-title":"Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation","volume":"116","author":"Sanchez","year":"2002","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.08.007_bib0029","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.bbmt.2012.02.012","article-title":"Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival","volume":"18","author":"Bachanova","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2025.08.007_bib0030","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/bmt.2012.147","article-title":"Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL","volume":"48","author":"Sanchez-Garcia","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2025.08.007_bib0031","article-title":"Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"2014","author":"Bar","year":"2014","journal-title":"Leuk Res Treat"},{"issue":"1","key":"10.1016\/j.clml.2025.08.007_bib0032","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bmt.2016.194","article-title":"Multi center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes","volume":"52","author":"Brammer","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.clml.2025.08.007_bib0033","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/10428194.2017.1369072","article-title":"Impact of clinical utility of MRD assessment with different techniques on survival in acute b lymphoblastic leukemia","volume":"59","author":"Huang","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2025.08.007_bib0034","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajh.25417","article-title":"Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts","volume":"94","author":"Zhao","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.08.007_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2018.07.012","article-title":"A seven-color panel including CD34 and TdT could be applied in >97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype","volume":"72","author":"Wang","year":"2018","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.clml.2025.08.007_bib0036","doi-asserted-by":"crossref","first-page":"E381","DOI":"10.1002\/ajh.25262","article-title":"Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission","volume":"93","author":"How","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.08.007_bib0037","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10555-019-09834-0","article-title":"Immunotherapy in pediatric acute lymphoblastic leukemia","volume":"38","author":"Inaba","year":"2019","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"10.1016\/j.clml.2025.08.007_bib0038","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2025.08.007_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.07.022","article-title":"Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received Venetoclax + Azacitidine versus intensive chemotherapy","volume":"28","author":"Winters","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.clml.2025.08.007_bib0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jtct.2022.03.017","volume":"28","author":"Kaito","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2025.08.007_bib0041","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.clml.2025.08.007_bib0042","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1002\/ajh.26789","article-title":"Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission","volume":"98","author":"Pasvolsky","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.08.007_bib0043","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/bloodadvances.2018027003","article-title":"The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia","volume":"3","author":"Yeshurun","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2025.08.007_bib0044","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17474086.2023.2273847","article-title":"The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Maurer","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"10.1016\/j.clml.2025.08.007_bib0045","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT)","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2025.08.007_bib0046","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41409-018-0293-3","article-title":"High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease","volume":"54","author":"Kraft","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.clml.2025.08.007_bib0047","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41409-023-01951-3","article-title":"Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists","volume":"58","author":"Mahmoudjafari","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.clml.2025.08.007_bib0048","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1182\/bloodadvances.2019001242","article-title":"Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort","volume":"4","author":"Schoettler","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2025.08.007_bib0049","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jtct.2022.08.003","article-title":"Defibrotide shows efficacy in the prevention of sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: a retrospective study","volume":"28","author":"Chalandon","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"22","key":"10.1016\/j.clml.2025.08.007_bib0050","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.3390\/jcm13226917","article-title":"Hepatic sinusoidal obstruction syndrome\/veno-occlusive disease (SOS\/VOD) primary prophylaxis in patients undergoing hematopoietic stem cell transplantation: A network meta-analysis of randomized controlled trials","volume":"13","author":"Sousa-Pimenta","year":"2024","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.clml.2025.08.007_bib0051","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3390\/ijms24021159","article-title":"Transplant-associated thrombotic microangiopathy in the context of allogenic hematopoietic stem cell transplantation: where we stand","volume":"24","author":"Lazana","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:19:05Z","timestamp":1776741545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265025002848"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Impact of the Level of Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation on Pediatric Patients With Acute Lymphoblastic Leukemia: A 10-Year Single-Center Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}